(VIANEWS) – The NASDAQ ended the session with Insulet (PODD) jumping 15.34% to $161.99 on Saturday while NASDAQ rose 1.38% to $13,478.28.
Insulet’s last close was $140.44, 58.19% under its 52-week high of $335.91.
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Earnings Per Share
As for profitability, Insulet has a trailing twelve months EPS of $0.9.
PE Ratio
Insulet has a trailing twelve months price to earnings ratio of 179.99. Meaning, the purchaser of the share is investing $179.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.88%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Insulet’s stock is considered to be oversold (<=20).
More news about Insulet (PODD).
